NCT00062127View on ClinicalTrials.gov

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2006

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

Given IV

DRUG

thalidomide

Given orally

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00062127 - Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter